CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, B.
Right arrow Articles by Chin, K. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, B.
Right arrow Articles by Chin, K. V.

Cell Growth & Differentiation, Vol 7, Issue 8 1105-1112, Copyright © 1996 by American Association of Cancer Research


ARTICLES

Cisplatin resistance and regulation of DNA repair in cAMP-dependent protein kinase mutants

B Liu, ME Cvijic, A Jetzt and KV Chin
Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway 08854, USA.

Drug resistance in cancer poses a major problem to the success of chemotherapy. Increased resistance to the DNA-damaging chemotherapeutic drug cisplatin may be associated with a variety of factors including decreased drug accumulation, increased intracellular levels of thiols, and increased DNA repair. We have found that mutants of the Chinese hamster ovary (CHO) and the mouse adrenocortical carcinoma Y1 cells harboring a defective regulatory subunit (RI) of the cAMP-dependent protein kinase (PKA) exhibited increased resistance to cisplatin. These mutants are cross-resistant to other DNA-damaging chemotherapeutic agents, including bleomycin and melphalan. In addition, wild-type CHO cells transfected with and overexpressing the yeast phosphodiesterase gene or a dominant mutant Rl alpha subunit gene also displayed similar increased resistance to cisplatin. However, mutants with altered catalytic (C) subunits showed a sensitivity to cisplatin similar to the wild-type cells. Further analysis by gel shift assay using cisplatin-damaged DNA as probes and nuclear extracts derived from the Rl subunit mutants showed increased binding of nuclear factor(s) to the damaged DNA. In addition, a host cell reactivation assay of DNA repair, using a cisplatin-damaged reporter plasmid, detected enhanced capacity for repair of DNA lesions in the PKA mutants. These results suggest that DNA repair may be increased in the PKA mutants. We speculate that functional inactivation of PKA may result in increased DNA repair and the acquisition of resistance to DNA-damaging anticancer drugs in cancer.


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
M. V. Nesterova and Y. S. Cho-Chung
Antisense Protein Kinase A RI{alpha} Inhibits 7,12-Dimethylbenz(a)anthracene-Induction of Mammary Cancer: Blockade at the Initial Phase of Carcinogenesis
Clin. Cancer Res., July 1, 2004; 10(13): 4568 - 4577.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
H. Niedner, R. Christen, X. Lin, A. Kondo, and S. B. Howell
Identification of Genes That Mediate Sensitivity to Cisplatin
Mol. Pharmacol., December 1, 2001; 60(6): 1153 - 1160.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. E. Cvijic, T. Kita, W. Shih, R. S. DiPaola, and K.-V. Chin
Extracellular Catalytic Subunit Activity of the cAMP-dependent Protein Kinase in Prostate Cancer
Clin. Cancer Res., June 1, 2000; 6(6): 2309 - 2317.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1996 by the American Association of Cancer Research.